RÉSUMÉ
BACKGROUND: Kidney and life outcomes remain unsatisfactory in patients with microscopic polyangiitis (MPA). Appropriate treatment intensity must be provided to the appropriate patients. To identify severe cases early, we investigated the factors related to kidney and life outcomes. METHODS: We included patients diagnosed with MPA based on myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) positivity and kidney histopathology results after kidney biopsies between January 1, 2021, and May 11, 2023, at 10 affiliated centers, including our hospital. Death, maintenance dialysis, and estimated glomerular filtration rate (eGFR) < 15 after 6 months of treatment were defined as poor prognosis groups, and factors associated with these conditions were investigated. RESULTS: We included 84 (36 men and 48 women) patients in this study. Median age was 73.8 (interquartile range: 71-81) years. After 6 months of treatment, the proportion of patients in the poor prognosis group was 16.7 %, with a mortality of 7.1 % and a poor kidney prognosis rate of 9.5 %. Area under the receiver operating characteristic curve showed that eGFR at 2 weeks had a comparable prognostic performance equal as eGFR at 4 weeks (area under the curve: 0.875 and 0.896, respectively). After adjustment by various factors, eGFR at 2 weeks was related with prognosis significantly (p = 0.031). CONCLUSION: Kidney function 2 weeks after the start of treatment for MPA can predict prognosis.
Sujet(s)
Anticorps anti-cytoplasme des polynucléaires neutrophiles , Débit de filtration glomérulaire , Polyangéite microscopique , Humains , Polyangéite microscopique/traitement médicamenteux , Polyangéite microscopique/mortalité , Polyangéite microscopique/diagnostic , Mâle , Femelle , Sujet âgé , Sujet âgé de 80 ans ou plus , Pronostic , Anticorps anti-cytoplasme des polynucléaires neutrophiles/sang , Facteurs temps , Études rétrospectives , Rein/anatomopathologie , Rein/physiopathologie , Myeloperoxidase/immunologie , Immunosuppresseurs/usage thérapeutique , Dialyse rénale , Résultat thérapeutiqueRÉSUMÉ
PURPOSE: We evaluated (1) whether participating in middle- and long-distance running races augments muscle soreness, oxygen cost, respiration, and exercise exertion during subsequent running, and (2) if post-race menthol application alleviates these responses in long-distance runners. METHODS: Eleven long-distance runners completed a 1500-m race on day 1 and a 3000-m race on day 2. On day 3 (post-race day), either a 4% menthol solution (Post-race menthol) or a placebo solution (Post-race placebo) serving as a vehicle control, was applied to their lower leg skin, and their perceptual and physiological responses were evaluated. The identical assessment with the placebo solution was also conducted without race participation (No-race placebo). RESULTS: The integrated muscle soreness index increased in the Post-race placebo compared to the No-race placebo (P < 0.001), but this response was absent in the Post-race menthol (P = 0.058). Oxygen uptake during treadmill running tended to be higher (4.3%) in the Post-race placebo vs. No-race placebo (P = 0.074). Oxygen uptake was 5.4% lower in the Post-race menthol compared to the Post-race placebo (P = 0.018). Minute ventilation during treadmill running was 6.7-7.6% higher in the Post-race placebo compared to No-race placebo, whereas it was 6.6-9.0% lower in the Post-race menthol vs. Post-race placebo (all P ≤ 0.001). The rate of perceived exertion was 7.0% lower in the Post-race menthol vs. Post-race placebo (P = 0.007). CONCLUSIONS: Middle- and long-distance races can subsequently elevate muscle soreness and induce respiratory and metabolic stress, but post-race menthol application to the lower legs can mitigate these responses and reduce exercise exertion in long-distance runners.
Sujet(s)
Menthol , Myalgie , Consommation d'oxygène , Course à pied , Humains , Menthol/pharmacologie , Menthol/administration et posologie , Mâle , Adulte , Course à pied/physiologie , Consommation d'oxygène/effets des médicaments et des substances chimiques , Femelle , Muscles squelettiques/effets des médicaments et des substances chimiques , Muscles squelettiques/métabolisme , Jeune adulteRÉSUMÉ
Background: The coronavirus disease 2019 (COVID-19) pandemic significantly affected the lives of Japanese collegiate men's basketball players. Purpose: To describe the incidence of lower extremity injuries in Japanese collegiate men's basketball during the COVID-19 pandemic and examine the effects of the pandemic on injury patterns. Study Design: Descriptive epidemiological study. Methods: Using data from a surveillance project of the Department of Medicine and Science of the Kanto Collegiate Basketball Federation, the authors included data from 6 men's basketball teams during the 2020-21 and 2021-22 seasons (11 team seasons). Injury rates per 1000 athlete-exposures (AEs) were calculated according to injury type, location, and frequency. Injury burden was estimated by multiplying the injury rate by the mean days lost. Injuries from the 2020-21 to 2021-22 seasons were compared with those before the pandemic (2013-14 to 2019-20 seasons) using injury rate ratios (IRRs), with significant differences indicated when the 95% CI did not include 1.0. Results: In total, 135 lower extremity injuries were reported during 27,249 AEs. The overall injury rate of the 2020-21 to 2021-22 seasons was significantly higher than that of the 2013-14 to 2019-20 seasons (IRR, 1.37; 95% CI, 1.12-1.67). Lateral ankle sprains (IRR, 1.37; 95% CI, 1.02-1.86), hamstring strains (IRR, 2.86; 95% CI, 1.34-6.12), jumper's knee (IRR, 2.68; 95% CI, 1.13-6.37), and stress fractures of the proximal fifth metatarsal (IRR, 7.16; 95% CI, 1.31-39.08) were significantly higher during the 2020-21 to 2021-22 seasons compared with the 2013-14 to 2019-20 seasons. Conclusion: The rate of lower extremity injuries increased significantly in Japanese collegiate men's basketball players during the COVID-19 pandemic. The results of this study emphasize the importance of optimal screening and specific loads for injury prevention when detraining periods are anticipated.
RÉSUMÉ
INTRODUCTION: In women, the female athlete triad, marked by low energy availability, functional hypothalamic amenorrhea and osteoporosis, is a recognized risk for stress fractures. Stress injuries also occur in men, but by contrast risks and mechanisms underlying them are less characterized. MATERIALS AND METHODS: 5 week-old wild-type male mice were fed ad libitum (ad) or subjected to 60% food restriction (FR) for five weeks. In both groups, some mice were allowed access to an exercise wheel in cages to allow voluntary wheel running (ex) and/or treated with active vitamin D analogues. Mice were sacrificed and analyzed at 10 weeks of age. RESULT: Male FR mice exhibited significantly reduced testicle weight, serum testosterone levels and bone mass. Such bone losses in FR male mice were enhanced by exercise. Histological analysis revealed that both bone-resorbing and -forming activities were significantly reduced in FR or FR plus exercise (FR + ex) mice, mimicking a state of low bone turnover. Significantly reduced bone mass in FR or FR + ex male mice was significantly rescued by treatment with active vitamin D analogues, with significant restoration of osteoblastic activities. Serum levels of insulin-like growth factor I (IGF-I), which is critical for bone remodeling, were significantly lower in FR versus control male mice. CONCLUSIONS: Low energy availability puts men at risk for stress injuries as well, and low energy availability is upstream of gonadal dysfunction and osteoporosis in males. Active vitamin D analogues could serve as therapeutic or preventive options for stress injuries in men.
Sujet(s)
Activité motrice , Ostéoporose , Femelle , Mâle , Souris , Animaux , Densité osseuse , Os et tissu osseux , Vitamine DRÉSUMÉ
Currently, implants are utilized clinically for bone transplant procedures. However, if infectious osteomyelitis occurs at implant sites, removal of bacteria can be challenging. Moreover, altered blood flow at peri-implant infectious sites can create an anaerobic environment, making it more difficult to treat infection with antibiotics. Thus, it would be beneficial if implants could be modified to exhibit antibacterial activity, even in anaerobic conditions. Here, we show antibacterial activity of silver ions coated on titanium rods, even against the anaerobic bacteria Porphyromonas gingivalis (P. gingivalis), both in vitro and in vivo. Specifically, we implanted silver-coated or control uncoated titanium rods along with P. gingivalis in mouse femoral bone BM cavities and observed significantly inhibited P. gingivalis infection with silver-coated compared with non-coated rods, based on in vivo bio-imaging. Osteonecrosis by infectious osteomyelitis and elevation of the inflammatory factors C-reactive protein and IL-6 promoted by P. gingivalis s were also significantly reduced in the presence of silver-coated rods. Overall, our study indicates that silver ion coating of an implant represents a therapeutic option to prevent associated infection, even in anaerobic conditions or against anaerobic bacteria.
Sujet(s)
Antibactériens , Bactéries anaérobies , Matériaux revêtus, biocompatibles , Implants expérimentaux , Ostéomyélite , Argent , Animaux , Souris , Antibactériens/pharmacologie , Bactéries anaérobies/effets des médicaments et des substances chimiques , Matériaux revêtus, biocompatibles/pharmacologie , Ions/pharmacologie , Ostéomyélite/microbiologie , Ostéomyélite/prévention et contrôle , Argent/pharmacologie , Titane/composition chimique , Porphyromonas gingivalis/effets des médicaments et des substances chimiques , Implants expérimentaux/effets indésirables , Implants expérimentaux/microbiologie , Fémur , Protéine C-réactiveRÉSUMÉ
Background: While the risk of exceeding the standard range of phosphorus levels has been investigated, the impact of the degree of fluctuations has not been investigated. Methods: Data were derived from the Japan Dialysis Active Vitamin D trial, a 4-year prospective, randomized study involving 976 patients without secondary hyperparathyroidism undergoing hemodialysis in Japan. Laboratory data were collected every 6 months and the primary outcome was the time to the occurrence of cardiovascular events. The effect of time-dependent changes in phosphorus levels was assessed using a time-varying Cox proportional hazards regression model. Results: The median serum phosphorus levels at baseline and at the final observation were 4.70 mg/dl [interquartile range (IQR) 3.90-5.30] and 5.00 mg/dl (IQR 4.20-5.80), respectively. Over each 6-month period, phosphorus changes ranged from -7.1 to +6.7 mg/dl, with a median value of -0.1 to +0.3 mg/dl. During follow-up, composite cardiovascular events occurred in 103 of 964 patients. Although the P-value for the interaction between serum phosphorus level fluctuations and baseline phosphorus levels was insignificant, the following trends were observed. First, patients with relatively high initial phosphorus levels over a 6-month period showed a trend towards a higher hazard, with greater changes in the phosphorus level over the 6-month period. Second, it was suggested that oral vitamin D receptor activators could contribute to the relationship between fluctuating phosphorus levels and cardiovascular events. Conclusions: Our results suggest the importance of maintaining stable phosphorus levels, not only in the normal range, but also without fluctuations, in the risk of cardiovascular events among patients without secondary hyperparathyroidism undergoing maintenance hemodialysis.
RÉSUMÉ
Ossification of the posterior longitudinal ligament (OPLL), a disease characterized by the ectopic ossification of a spinal ligament, promotes neurological disorders associated with spinal canal stenosis. While blocking ectopic ossification is mandatory to prevent OPLL development and progression, the mechanisms underlying the condition remain unknown. Here we show that expression of hydroxyacid oxidase 1 (Hao1), a gene identified in a previous genome-wide association study (GWAS) as an OPLL-associated candidate gene, specifically and significantly decreased in fibroblasts during osteoblast differentiation. We then newly established Hao1-deficient mice by generating Hao1-flox mice and crossing them with CAG-Cre mice to yield global Hao1-knockout (CAG-Cre/Hao1flox/flox; Hao1 KO) animals. Hao1 KO mice were born normally and exhibited no obvious phenotypes, including growth retardation. Moreover, Hao1 KO mice did not exhibit ectopic ossification or calcification. However, urinary levels of some metabolites of the tricarboxylic acid (TCA) cycle were significantly lower in Hao1 KO compared to control mice based on comprehensive metabolomic analysis. Our data indicate that Hao1 loss does not promote ectopic ossification, but rather that Hao1 functions to regulate the TCA cycle in vivo.
RÉSUMÉ
Invasive dental treatment such as tooth extraction following treatment with strong anti-bone resorptive agents, including bisphosphonates and denosumab, reportedly promotes osteonecrosis of the jaw (ONJ) at the extraction site, but strategies to prevent ONJ remain unclear. Here we show that in mice, administration of either active vitamin D analogues, antibiotics or anti-inflammatory agents can prevent ONJ development induced by tooth extraction during treatment with the bisphosphonate zoledronate. Specifically, tooth extraction during treatment with zoledronate induced osteonecrosis in mice, but administration of either 1,25(OH)2D3 or ED71, both active vitamin D analogues, significantly antagonized osteonecrosis development, even under continuous zoledronate treatment. 1,25(OH)2D3 or ED71 administration also significantly inhibited osteocyte apoptosis induced by tooth extraction and bisphosphonate treatment. Administration of either active vitamin D analogue significantly inhibited elevation of serum inflammatory cytokine levels in mice in response to injection of lipopolysaccharide, an infection mimetic. Furthermore, administration of either anti-inflammatory or antibiotic reagents significantly blocked ONJ development following tooth extraction and zoledronate treatment. These findings suggest that administration of active vitamin D, anti-inflammatory agents or antibiotics could prevent ONJ development induced by tooth extraction in patients treated with zoledronate.
Sujet(s)
Antibactériens/administration et posologie , Anti-inflammatoires/administration et posologie , Ostéonécrose de la mâchoire associée aux biphosphonates/prévention et contrôle , Extraction dentaire/effets indésirables , Vitamine D/administration et posologie , Acide zolédronique/effets indésirables , Animaux , Apoptose/effets des médicaments et des substances chimiques , Ostéonécrose de la mâchoire associée aux biphosphonates/sang , Ostéonécrose de la mâchoire associée aux biphosphonates/étiologie , Cytokines/sang , Diphosphonates/effets indésirables , Femelle , Humains , Souris de lignée C57BL , Ostéocytes/cytologie , Ostéocytes/effets des médicaments et des substances chimiques , Vitamine D/analogues et dérivésRÉSUMÉ
Stomata-small pores generally found on the leaves of plants-control gas exchange between plant and the atmosphere. Elucidating the mechanism that underlies such control through the regulation of stomatal opening/closing is important to understand how plants regulate photosynthesis and tolerate against drought. However, up-to-date, molecular components and their function involved in stomatal regulation are not fully understood. We challenged such problem through a chemical genetic approach by isolating and characterizing synthetic molecules that influence stomatal movement. Here, we describe that a small chemical collection, prepared during the development of C-H amination reactions, lead to the discovery of a Stomata Influencing Molecule (SIM); namely, a sulfonimidated oxazole that inhibits stomatal opening. The starting molecule SIM1 was initially isolated from screening of compounds that inhibit light induced opening of dayflower stomata. A range of SIM molecules were rapidly accessed using our state-of-the-art C-H amination technologies. This enabled an efficient structure-activity relationship (SAR) study, culminating in the discovery of a sulfonamidated oxazole derivative (SIM*) having higher activity and enhanced specificity against stomatal regulation. Biological assay results have shed some light on the mode of action of SIM molecules within the cell, which may ultimately lead to drought tolerance-conferring agrochemicals through the control of stomatal movement.
RÉSUMÉ
BACKGROUND: The benefits of vitamin D receptor activators (VDRAs) for patients with chronic kidney disease are well recognized. However, the optimal criteria for patient selection, dosage forms, and duration providing the highest benefit and the least potential risk remain to be confirmed. MATERIALS AND METHODS: The study population was derived from the Aichi Cohort Study of Prognosis in Patients Newly Initiated into Dialysis, a multicenter prospective cohort study of 1520 incident dialysis patients. According to the VDRA usage status in March 2015 (interim report), the 967 patients surviving after March 2015 were classified into three groups: without VDRA (NV, n = 177), oral VDRA (OV, n = 447), and intravenous VDRA (IV, n = 343). Mortality rates were compared using the log-rank test, and factors contributing to all-cause mortality were examined using both univariate and multivariate Cox proportional hazard regression analyses. RESULTS: There were 104 deaths (NV, n = 27; OV, n = 53; IV, n = 24) during the follow-up period (1360 days, median), and significant differences in cumulative survival rates were observed between the three groups (p = 0.010). Moreover, lower all-cause mortality was associated with IV versus NV (hazard ratio, 0.46 [95% confidence interval 0.24-0.89]; p = 0.020). CONCLUSION: This study demonstrated the impact of the VDRA dosage form on the short-term survival of incident hemodialysis patients during the introduction period. Our results suggest that relatively early initiation of intravenous VDRA in patients beginning hemodialysis may have some clinical potential.
Sujet(s)
Récepteur calcitriol/administration et posologie , Dialyse rénale/méthodes , Insuffisance rénale chronique/traitement médicamenteux , Insuffisance rénale chronique/mortalité , Administration par voie intraveineuse , Administration par voie orale , Sujet âgé , Cause de décès , Relation dose-effet des médicaments , Calendrier d'administration des médicaments , Femelle , Humains , Japon , Mâle , Adulte d'âge moyen , Études prospectives , Insuffisance rénale chronique/thérapie , Facteurs de risque , Analyse de survie , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
Skeletal muscle is known to regulate bone homeostasis through muscle-bone interaction, although factors that control this activity remain unclear. Here, we newly established Smad3-flox mice, and then generated skeletal muscle-specific Smad2/Smad3 double conditional knockout mice (DcKO) by crossing Smad3-flox with skeletal muscle-specific Ckmm Cre and Smad2-flox mice. We show that immobilization-induced gastrocnemius muscle atrophy occurring due to sciatic nerve denervation was partially but significantly inhibited in DcKO mice, suggesting that skeletal muscle cell-intrinsic Smad2/3 is required for immobilization-induced muscle atrophy. Also, tibial bone atrophy seen after sciatic nerve denervation was partially but significantly inhibited in DcKO mice. Bone formation rate in wild-type mouse tibia was significantly inhibited by immobilization, but inhibition was abrogated in DcKO mice. We propose that skeletal muscle regulates immobilization-induced bone atrophy via Smad2/3, and Smad2/3 represent potential therapeutic targets to prevent both immobilization-induced bone and muscle atrophy.
Sujet(s)
Muscles squelettiques/métabolisme , Amyotrophie/génétique , Amyotrophie/prévention et contrôle , Nerf ischiatique/traumatismes , Protéine Smad2/génétique , Protéine Smad-3/génétique , Animaux , Croisements génétiques , Femelle , Régulation de l'expression des gènes , Integrases/génétique , Integrases/métabolisme , Mâle , Souris , Souris knockout , Dénervation musculaire/méthodes , Protéines du muscle/génétique , Protéines du muscle/métabolisme , Muscles squelettiques/innervation , Muscles squelettiques/anatomopathologie , Amyotrophie/métabolisme , Amyotrophie/anatomopathologie , SKP cullin F-box protein ligases/génétique , SKP cullin F-box protein ligases/métabolisme , Transduction du signal , Protéine Smad2/déficit , Protéine Smad-3/déficit , Tibia/innervation , Tibia/métabolisme , Protéines à motif tripartite/génétique , Protéines à motif tripartite/métabolisme , Ubiquitin-protein ligases/génétique , Ubiquitin-protein ligases/métabolismeRÉSUMÉ
BACKGROUND: Although various reconstruction techniques are available for anterior cruciate ligament (ACL) injuries, a long recovery time is required before patients return to sports activities, as the reconstructed ACL requires time to regain strength. To date, several studies have reported use of mesenchymal stem cells in orthopaedic surgery; however, no studies have used adipose-derived stem cell (ADSC) sheets in ACL reconstruction (ACLR). HYPOTHESIS: ADSC sheet transplantation can improve biomechanical strength of the autograft used in ACLR. STUDY DESIGN: Controlled laboratory study. METHODS: A total of 68 healthy Japanese white rabbits underwent unilateral ACLR with a semitendinosus tendon autograft after random enrollment into a control group (no sheet; n = 34) and a sheet group (ADSC sheet; n = 34). At 2, 4, 8, 16, and 24 weeks after surgery, rabbits in each group were sacrificed to evaluate tendon-bone healing using histological staining, micro-computed tomography, and biomechanical testing. At 24 weeks, scanning transmission electron microscopy of the graft midsubstance was performed. RESULTS: The ultimate failure load for the control and sheet groups, respectively, was as follows: 17.2 ± 5.5 versus 37.3 ± 10.3 (P = .01) at 2 weeks, 28.6 ± 1.9 versus 47.4 ± 10.4 (P = .003) at 4 weeks, 53.0 ± 14.3 versus 48.1 ± 9.3 (P = .59) at 8 weeks, 66.2 ± 9.3 versus 95.2 ± 43.1 (P = .24) at 16 weeks, and 66.7 ± 27.3 versus 85.3 ± 29.5 (P = .39) at 24 weeks. The histological score was also significantly higher in the sheet group compared with the control group at early stages up to 8 weeks. On micro-computed tomography, relative to the control group, the bone tunnel area was significantly narrower in the sheet group at 4 weeks, and the bone volume/tissue volume of the tendon-bone interface was significantly greater at 24 weeks. Scanning transmission electron microscopy at 24 weeks indicated that the mean collagen fiber diameter in the midsubstance was significantly greater, as was the occupation ratio of collagen fibers per field of view, in the sheet group. CONCLUSION: ADSC sheets improved biomechanical strength, prevented bone tunnel enlargement, and promoted tendon-bone interface healing and graft midsubstance healing in an in vivo rabbit model. CLINICAL RELEVANCE: ADSC sheets may be useful for early tendon-bone healing and graft maturation in ACLR.
Sujet(s)
Lésions du ligament croisé antérieur , Reconstruction du ligament croisé antérieur , Animaux , Humains , Lapins , Ligament croisé antérieur/chirurgie , Lésions du ligament croisé antérieur/chirurgie , Cellules souches , Microtomographie aux rayons XSujet(s)
Polykystoses rénales , Polykystose rénale autosomique dominante , Médecine factuelle , Pratique factuelle , Humains , Polykystoses rénales/diagnostic , Polykystoses rénales/génétique , Polykystoses rénales/thérapie , Polykystose rénale autosomique dominante/diagnostic , Polykystose rénale autosomique dominante/traitement médicamenteuxRÉSUMÉ
Changes in bone metabolism occur in mothers during pregnancy or lactation that may decrease bone mass and result in fragility fractures after partum. However, use of drugs during pregnancy or lactation to counteract these effects is often prohibited or strongly discouraged. Therefore, approaches to protect mothers from fragility fractures have not been established. Here we show that bone mineral density was significantly lower in female mice after partum than in age-matched female mice without partum. We also show that temporary administration of the bisphosphonate alendronate, either just before or just after pregnancy, to female mice was protective against bone loss due to pregnancy or lactation and had no adverse effects on offspring, such as growth retardation. Furthermore, we show that alendronate administration to female mice during lactation was effective in increasing bone mass in mothers without promoting bone abnormalities or growth retardation in offspring. Calcium levels in milk from female mice administered alendronate during lactation were equivalent to those in milk from mothers not treated with alendronate. Overall, we propose that alendronate administration to mothers could prevent bone loss and fragility fractures during pregnancy and lactation.
Sujet(s)
Alendronate , Préparations pharmaceutiques , Alendronate/pharmacologie , Alendronate/usage thérapeutique , Animaux , Densité osseuse , Femelle , Humains , Lactation , Souris , Mères , GrossesseRÉSUMÉ
Auto-inflammatory syndromes are rare diseases characterized by arthritis and joint destruction, symptoms similar to but distinct from rheumatoid arthritis (RA). Therapeutic targets have not been well characterized for auto-inflammatory syndromes, although the E3 ligase Synoviolin was previously shown to be a novel therapeutic target for RA. Here, we show that Synoviolin loss has little impact on a model of auto-inflammatory diseases. We previously established such a model, the hIL-1 cTg mouse, in which IL-1 signaling was constitutively activated, and animals exhibit symptoms recapitulating auto-inflammatory syndromes such as major joint dominant arthritis. Here, we crossed hIL-1 cTg with Synoviolin flox'd mice to yield hIL-1 cTg/Synoviolin cKO mice. Synoviolin gene expression was ablated in adult hIL-1 cTg/Synoviolin cKO mice by injection of pIpC to activate Mx1 promoter-driven Cre recombinase. However, symptoms seen in hIL-1 cTg mice such as arthritis and joint destruction were not alleviated by targeting Synoviolin, ruling out Synoviolin as a therapeutic target for auto-inflammatory disease. Our results indicate that although similar, RA and auto-inflammatory diseases are different diseases, and treatment strategies should differ accordingly.
Sujet(s)
Maladies auto-immunes/étiologie , Inflammation/étiologie , Ubiquitin-protein ligases/métabolisme , Animaux , Arthrite expérimentale/étiologie , Arthrite expérimentale/génétique , Arthrite expérimentale/métabolisme , Maladies auto-immunes/génétique , Maladies auto-immunes/métabolisme , Cytokines/métabolisme , Humains , Inflammation/génétique , Inflammation/métabolisme , Médiateurs de l'inflammation/métabolisme , Interleukine-1/génétique , Interleukine-1/métabolisme , Articulations/métabolisme , Articulations/anatomopathologie , Mâle , Souris , Souris de lignée C57BL , Souris knockout , Souris transgéniques , Protéines recombinantes/génétique , Protéines recombinantes/métabolisme , Ubiquitin-protein ligases/déficit , Ubiquitin-protein ligases/génétique , Facteurs de virulence/déficit , Facteurs de virulence/génétique , Facteurs de virulence/métabolismeRÉSUMÉ
Estrogen deficiency can be caused by ovarian dysfunction in females. Mechanisms underlying osteoporosis in this condition have been characterized in animal models, such as ovariectomized mice and rats, although it remains unclear how hypothalamic dysfunction promotes osteoporosis. Here, we show that administration of a gonadotropin-releasing hormone antagonist (GnRHa) significantly decreases uterine weight, a manifestation of hypothalamic dysfunction, and promotes both cortical and trabecular bone loss in female mice in vivo. We also report that osteoclast number significantly increased in mice administered GnRHa, and that the transcription factor hypoxia inducible factor 1 alpha (HIF1α) accumulated in those osteoclasts. We previously reported that treatment of mice with the active vitamin D analogue ED71, also known as eldecalcitol, inhibited HIF1α accumulation in osteoclasts. We show here that in mice, co-administration of ED71 with GnRHa significantly rescued the reduced cortical and trabecular bone mass promoted by GnRHa administration alone. GnRHa-dependent HIF1α accumulation in osteoclasts was also blocked by co-administration of ED71. We conclude that hypothalamic dysfunction promotes HIF1α accumulation in osteoclasts and likely results in reduced bone mass. We conclude that treatment with ED71 could serve as a therapeutic option to counter osteoporotic conditions in humans.
RÉSUMÉ
INTRODUCTION: Osteonecrosis of the jaw (ONJ) occurring after invasive dental treatment often adversely affects patients' activities of daily living. Long-term administration of strong anti-bone resorptive agents such as bisphosphonates prior to invasive dental treatment is considered an ONJ risk factor; however, pathological mechanisms underlying ONJ development remain unclear. MATERIALS AND METHODS: We developed an ONJ mouse model in which a tooth is extracted during treatment with the bisphosphonate zoledronate. RESULTS: We observed induction of apoptosis in osteocytes, resulting in formation of empty lacunae in jaw bones at sites of tooth extraction but not in other bones of the same mice. We also observed elevated levels of inflammatory cytokines such as TNFα, IL-6 and IL-1 in jaw bone at the extraction site relative to other sites in zoledronate-treated mice. We also report that treatment in vitro with either zoledronate or an extract from Porphyromonas gingivalis, an oral bacteria, promotes expression of inflammatory cytokines in osteoclast progenitor cells. We demonstrate that gene-targeting of either TNFα, IL-6 or IL-1 or treatment with etanercept, a TNFα inhibitor, or a neutralizing antibody against IL-6 can antagonize ONJ development caused by combined tooth extraction and zoledronate treatment. CONCLUSIONS: Taken together, the cytokine storm induced by invasive dental treatment under bisphosphonate treatment promotes ONJ development due to elevated levels of inflammatory cytokine-producing cells. Our work identifies novel targets potentially useful to prevent ONJ.
Sujet(s)
Ostéonécrose de la mâchoire associée aux biphosphonates/anatomopathologie , Cytokines/métabolisme , Médiateurs de l'inflammation/métabolisme , Extraction dentaire/effets indésirables , Acide zolédronique/effets indésirables , Animaux , Apoptose/effets des médicaments et des substances chimiques , Ostéonécrose de la mâchoire associée aux biphosphonates/microbiologie , Agents de maintien de la densité osseuse/effets indésirables , Transdifférenciation cellulaire/effets des médicaments et des substances chimiques , Syndrome de libération de cytokines/complications , Modèles animaux de maladie humaine , Femelle , Macrophages/effets des médicaments et des substances chimiques , Macrophages/métabolisme , Macrophages/anatomopathologie , Souris de lignée C57BL , Modèles biologiques , Ostéoclastes/effets des médicaments et des substances chimiques , Ostéoclastes/anatomopathologie , Ostéocytes/effets des médicaments et des substances chimiques , Ostéocytes/anatomopathologie , Ostéogenèse/effets des médicaments et des substances chimiques , Porphyromonas gingivalis/physiologie , Facteurs de risqueRÉSUMÉ
Low energy availability in female athletes often causes hypothalamic amenorrhea and osteoporosis, in turn promoting stress fractures. Mechanisms underlying these conditions remain unclear. Here we show that model mice subjected to food restriction (FR) or FR-plus-voluntary running exercise exhibit significantly reduced bone mineral density, cortical bone parameters and uterine weight than do control mice, and that these parameters worsen in the FR-plus-exercise group. Relative to controls, FR and FR-plus-exercise groups showed significantly lower mineral apposition rate and osteoclast number and significantly reduced serum insulin-like growth factor-1 (IGF1) levels. Outcomes were rescued by ED71 or 1.25(OH)2D3 treatment. Thus, we conclude that administration of active vitamin D analogues represents a possible treatment to prevent these conditions.
Sujet(s)
Os cortical , Privation alimentaire/physiologie , Facteur de croissance IGF-I/métabolisme , Ostéoporose/étiologie , Conditionnement physique d'animal , Utérus/anatomopathologie , Animaux , Atrophie , Densité osseuse , Calcitriol/usage thérapeutique , Os cortical/imagerie diagnostique , Os cortical/effets des médicaments et des substances chimiques , Femelle , Souris de lignée C57BL , Ostéoporose/imagerie diagnostique , Ostéoporose/traitement médicamenteux , Vitamine D/analogues et dérivés , Vitamine D/usage thérapeutiqueRÉSUMÉ
Vitamin D deficiency is a recognized risk factor for sarcopenia development, but mechanisms underlying this outcome are unclear. Here, we show that low vitamin D status worsens immobilization-induced muscle atrophy in mice. Mice globally lacking vitamin D receptor (VDR) exhibited more severe muscle atrophy following limb immobilization than controls. Moreover, immobilization-induced muscle atrophy was worse in neural crest-specific than in skeletal muscle-specific VDR-deficient mice. Tnfα expression was significantly higher in immobilized muscle of VDR-deficient relative to control mice, and was significantly elevated in neural crest-specific but not muscle-specific VDR-deficient mice. Furthermore, muscle atrophy induced by limb immobilization in low vitamin D mice was significantly inhibited in Tnfα-deficient mice. We conclude that vitamin D antagonizes immobilization-induced muscle atrophy via VDR expressed in neural crest-derived cells.